Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leukocyte-Poor Platelet-Rich Plasma (Steadman Philippon Research Institute)
- Development stage
- Unknown
- Lead developer
- Steadman Philippon Research Institute
- Administration
- Intraarticular
01
Overview
Leukocyte-Poor Platelet-Rich Plasma (LP-PRP) is an autologous biologic therapy derived from a patient's own blood. It is processed to contain a high concentration of platelets while minimizing the presence of white blood cells (leukocytes), particularly neutrophils, which are thought to potentially induce unwanted inflammatory responses in joint tissues. The Steadman Philippon Research Institute is investigating LP-PRP as an adjunct treatment following anterior cruciate ligament reconstruction (ACLR). The therapeutic effect is mediated by the release of high concentrations of growth factors from platelet alpha-granules, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). These factors promote cellular proliferation, collagen synthesis, and angiogenesis, thereby accelerating the healing of the ACL graft and surrounding joint tissues.
- Other names
- Platelet-Rich PlasmaPRP
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)FGFR3 (Fibroblast growth factor receptor 3)TGFBR (TGF-beta receptor)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on Leukocyte-Poor Platelet-Rich Plasma (Steadman Philippon Research Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leukocyte-Poor Platelet-Rich Plasma (Steadman Philippon Research Institute).